ES2069715T3 - Secuencia de oligonucleotidos antisentido, anti-arn mensajero del tnf alfa, procedimiento de preparacion, aplicacion como medicamentos y composiciones farmaceuticas. - Google Patents
Secuencia de oligonucleotidos antisentido, anti-arn mensajero del tnf alfa, procedimiento de preparacion, aplicacion como medicamentos y composiciones farmaceuticas.Info
- Publication number
- ES2069715T3 ES2069715T3 ES90402329T ES90402329T ES2069715T3 ES 2069715 T3 ES2069715 T3 ES 2069715T3 ES 90402329 T ES90402329 T ES 90402329T ES 90402329 T ES90402329 T ES 90402329T ES 2069715 T3 ES2069715 T3 ES 2069715T3
- Authority
- ES
- Spain
- Prior art keywords
- sequence
- application
- pharmaceutical compositions
- messenger rna
- preparation procedure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 2
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 2
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02K—DYNAMO-ELECTRIC MACHINES
- H02K2203/00—Specific aspects not provided for in the other groups of this subclass relating to the windings
- H02K2203/03—Machines characterised by the wiring boards, i.e. printed circuit boards or similar structures for connecting the winding terminations
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thin Magnetic Films (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
Abstract
LA SOLICITUD SE REFIERE A UNA SECUENCIA DE OLIGONUCLEOTIDOS ANTISENTIDO, ANTI-ARN MENSAJERO DEL TNF ALFA, DE FORMULA (I), EN LA QUE F ES HIDROGENO O UNA SECUENCIA DE 1 A 17 OLIGONUCLEOTIDOS EN FORMA LIBRE, ALCOHILADA, SULFURADA O DE DERIVADOS DE LA POLI L-LISINA, PROCEDIMIENTO DE PREPARACION, APLICACION COMO MEDICAMENTO Y COMPOSICIONES FARMACEUTICAS QUE CONTIENEN ESTA NUEVA SECUENCIA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8911171A FR2651130B1 (fr) | 1989-08-23 | 1989-08-23 | Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques. |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2069715T3 true ES2069715T3 (es) | 1995-05-16 |
Family
ID=9384878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES90402329T Expired - Lifetime ES2069715T3 (es) | 1989-08-23 | 1990-08-22 | Secuencia de oligonucleotidos antisentido, anti-arn mensajero del tnf alfa, procedimiento de preparacion, aplicacion como medicamentos y composiciones farmaceuticas. |
Country Status (19)
Country | Link |
---|---|
US (1) | US5705389A (es) |
EP (1) | EP0414607B1 (es) |
JP (1) | JPH0391485A (es) |
KR (1) | KR0151153B1 (es) |
CN (1) | CN1028760C (es) |
AT (1) | ATE120201T1 (es) |
AU (1) | AU642423B2 (es) |
CA (1) | CA2023899C (es) |
DE (1) | DE69017983T2 (es) |
DK (1) | DK0414607T3 (es) |
ES (1) | ES2069715T3 (es) |
FR (1) | FR2651130B1 (es) |
GR (1) | GR3015527T3 (es) |
HU (1) | HU215242B (es) |
IE (1) | IE68592B1 (es) |
IL (1) | IL95342A (es) |
PT (1) | PT95067B (es) |
RU (1) | RU2066325C1 (es) |
ZA (1) | ZA906675B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1250722B (it) * | 1991-07-30 | 1995-04-21 | Univ Degli Studi Milano | Oligonucleotidi antisenso |
TW323284B (es) * | 1992-03-23 | 1997-12-21 | Novartis Ag | |
EP0682705A1 (en) * | 1993-02-03 | 1995-11-22 | N.V. Innogenetics S.A. | Tnf-alpha muteins and a process for preparing them |
US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
AU1249299A (en) * | 1997-11-25 | 1999-06-15 | Brax Genomics Limited | Chimeric antisense oligonucleotides against tnf-alpha and their uses |
US20020077276A1 (en) * | 1999-04-27 | 2002-06-20 | Fredeking Terry M. | Compositions and methods for treating hemorrhagic virus infections and other disorders |
US20040006036A1 (en) * | 2000-04-12 | 2004-01-08 | Gmr, A Delaware Corporation | Silencing transcription by methylation |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
NZ598346A (en) * | 2002-07-19 | 2013-10-25 | Abbvie Biotechnology Ltd | Treatment of tnf alpha related disorders |
WO2006041970A2 (en) * | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
CA2903138A1 (en) | 2005-05-16 | 2006-11-23 | Abbvie Biotechnology Ltd. | Use of tnfa inhibitor for treatment of erosive polyarthritis |
US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
EP2007426A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS |
US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
CN101235064B (zh) * | 2008-02-27 | 2011-08-10 | 东南大学 | 可脱保护的硫代核苷酸单体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0090789A1 (en) * | 1982-03-26 | 1983-10-05 | Monsanto Company | Chemical DNA synthesis |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
FR2584090B1 (fr) | 1985-06-27 | 1987-08-28 | Roussel Uclaf | Nouveaux supports, leur preparation et les intermediaires obtenus, leur application a la synthese d'oligonucleotides et les nouveaux nucleosides et oligonucleotides relies aux supports ainsi obtenus |
AU1346488A (en) * | 1987-02-26 | 1988-09-26 | Cetus Corporation | Arginine-depleted human tumor necrosis factor |
JPH03505672A (ja) * | 1988-07-05 | 1991-12-12 | ベイラー カレッジ オブ メディシン | 高分子合成オペロンの相補アンチセンス オリゴヌクレオチド抗菌、バクテリヤ感染の処置方法 |
-
1989
- 1989-08-23 FR FR8911171A patent/FR2651130B1/fr not_active Expired - Fee Related
-
1990
- 1990-08-10 IL IL9534290A patent/IL95342A/en unknown
- 1990-08-22 DE DE69017983T patent/DE69017983T2/de not_active Expired - Lifetime
- 1990-08-22 KR KR1019900013041A patent/KR0151153B1/ko not_active IP Right Cessation
- 1990-08-22 ES ES90402329T patent/ES2069715T3/es not_active Expired - Lifetime
- 1990-08-22 PT PT95067A patent/PT95067B/pt not_active IP Right Cessation
- 1990-08-22 IE IE303690A patent/IE68592B1/en not_active IP Right Cessation
- 1990-08-22 AU AU61190/90A patent/AU642423B2/en not_active Expired
- 1990-08-22 ZA ZA906675A patent/ZA906675B/xx unknown
- 1990-08-22 AT AT90402329T patent/ATE120201T1/de not_active IP Right Cessation
- 1990-08-22 EP EP90402329A patent/EP0414607B1/fr not_active Expired - Lifetime
- 1990-08-22 DK DK90402329.8T patent/DK0414607T3/da active
- 1990-08-23 CN CN90107162A patent/CN1028760C/zh not_active Expired - Lifetime
- 1990-08-23 JP JP2220177A patent/JPH0391485A/ja active Pending
- 1990-08-23 HU HU905302A patent/HU215242B/hu unknown
- 1990-08-23 CA CA002023899A patent/CA2023899C/fr not_active Expired - Lifetime
-
1991
- 1991-12-24 RU SU915010468A patent/RU2066325C1/ru active
-
1994
- 1994-11-18 US US08/342,338 patent/US5705389A/en not_active Expired - Lifetime
-
1995
- 1995-03-23 GR GR940401796T patent/GR3015527T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK0414607T3 (da) | 1995-06-06 |
CN1049668A (zh) | 1991-03-06 |
GR3015527T3 (en) | 1995-06-30 |
IE903036A1 (en) | 1991-02-27 |
DE69017983T2 (de) | 1995-09-28 |
KR910004198A (ko) | 1991-03-28 |
CN1028760C (zh) | 1995-06-07 |
PT95067A (pt) | 1991-04-18 |
IL95342A (en) | 1995-01-24 |
EP0414607A2 (fr) | 1991-02-27 |
ATE120201T1 (de) | 1995-04-15 |
FR2651130B1 (fr) | 1991-12-13 |
CA2023899A1 (fr) | 1991-02-24 |
AU642423B2 (en) | 1993-10-21 |
JPH0391485A (ja) | 1991-04-17 |
IL95342A0 (en) | 1991-06-30 |
HUT56113A (en) | 1991-07-29 |
EP0414607A3 (en) | 1991-04-03 |
EP0414607B1 (fr) | 1995-03-22 |
CA2023899C (fr) | 2002-05-14 |
KR0151153B1 (ko) | 1998-08-17 |
AU6119090A (en) | 1991-02-28 |
HU215242B (hu) | 1998-11-30 |
FR2651130A1 (fr) | 1991-03-01 |
ZA906675B (en) | 1991-10-30 |
PT95067B (pt) | 1997-05-28 |
IE68592B1 (en) | 1996-06-26 |
US5705389A (en) | 1998-01-06 |
DE69017983D1 (de) | 1995-04-27 |
RU2066325C1 (ru) | 1996-09-10 |
HU905302D0 (en) | 1991-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2069715T3 (es) | Secuencia de oligonucleotidos antisentido, anti-arn mensajero del tnf alfa, procedimiento de preparacion, aplicacion como medicamentos y composiciones farmaceuticas. | |
AR020051A1 (es) | Procedimiento de uso y uso de una combinacion de un anticuerpo anti-erbb2 y un agente quimicoterapeutico distinto de un derivado de antraciclina para la manufactura de un medicamento util para el tratamiento de cancer | |
FI972628A0 (fi) | Uudet sulfonamidit | |
NZ251320A (en) | Bis-aromatic alpha,beta-unsaturated ketones, preparation and use in pharmaceutical compositions | |
EP0288163A3 (en) | Oligodeoxynucleotides as inhibitors of the replication of retroviruses and the expression of oncogenes | |
DE3584120D1 (de) | Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. | |
OA07419A (fr) | Activateur de plamimogène de tissu humain, son procédé de production et composition pharmaceutique le contenant. | |
SE8900586D0 (sv) | Komposition och foerfarande foer att foerhindra adhesion mellan kroppsvaevnader | |
ES2062073T3 (es) | Composiciones de tinta que contiene una mezcla de un poliester, un polimero acrilico y un polimero vinilico. | |
BR9813651A (pt) | Compostos antipicornavirais e métodos para o seu uso e preparação | |
EG18379A (en) | Novel pharmacological compounds | |
BR0015197A (pt) | Copolìmero vinìlico, e, composição | |
AR008387A1 (es) | Nuevas 5-fenoxialquil-tiazolidin-2,4-dionas, procedimientos para obtenerlas, nuevos compuestos intermedios de estos procedimientos ycomposiciones farmaceuticas que contienen las nuevas 5-fenoxialquil-tiazolidin- 2,4-dionas | |
DE59407457D1 (de) | Blockierung der anlagerung von keimen an menschliche zellen | |
ES2173858T3 (es) | Analogos de huperzina a. | |
BR9713921A (pt) | Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa | |
DE68912020D1 (de) | N-2,3-Butadienyl-tri-aminoalkanderivate. | |
ES2072975T3 (es) | Mezcla de esterilizante y metodo de esterilizacion. | |
EP0170269A3 (en) | Medicated cosmetic compositions | |
ES2129893T3 (es) | Dinucleosido-5',5'-pirofosfatos. | |
DE3762854D1 (de) | Pharmazeutische zusammensetzungen mit inhalt von 5-phenyl-1,3-dioxoalkenylverbindungen. | |
MX9303952A (es) | Barra limpiadora para acondicionar la piel o el cabello. | |
ES2010282A6 (es) | Procedimiento para reparar 8 -acilaminoergolina. | |
ES2152959T3 (es) | Utilizacion en perfumeria de isomeros opticamente activos del (e)-3,3-dimetil-5-(2,2,3-trimetil-3-ciclopenten-1-il)-4-penten-2-ol. | |
UA41037A (uk) | Препарат для лікування захворювань порожнини роту |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 414607 Country of ref document: ES |